Abstract
Summarizing our vision of hemato-oncology in the 21st century, we believe that with time, and with the expected progress in both medicine and biotechnology, the role of non-specific chemotherapy will decrease, while that of targeted therapies will increase. Unfortunately, for most tumors chemotherapy is still the cornerstone of treatment. We should therefore focus on finding more targeted agents, better tailoring of treatments, and identifying the risk factors for cancer development and the means of prevention of - what is likely to be - the number one killer of this century.
| Original language | English |
|---|---|
| Pages (from-to) | 843-844 |
| Number of pages | 2 |
| Journal | Israel Medical Association Journal |
| Volume | 8 |
| Issue number | 12 |
| State | Published - 1 Dec 2006 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hemato-oncology
- Tailored therapy
- Targeted therapy
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Targeted and tailored therapy in hemato-oncology: Vision for the 21st century'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver